帕金森病患者血清半胱氨酸蛋白酶抑制剂C水平的变化及其临床意义  

The clinical significance of serum cystatin C level change in Parkinson's disease

作　　者：叶明[1] 陈育华[1] 刘晓林[1] 许力[1] 许文芳[1] 谢静[1] 时鹏[1] 屈洪党[1] 

机构地区：[1]蚌埠医学院第一附属医院神经内科,安徽蚌埠233004

出　　处：《中华全科医学》2016年第12期2004-2007,共4页Chinese Journal of General Practice

基　　金：安徽省教育厅科研基金重点项目(KJ2014A163)

摘　　要：目的探讨血清半胱氨酸蛋白酶抑制剂C(胱抑素C,Cys-C)水平与帕金森病患者(Parkinson’s disease,PD)的相关性及临床意义。方法收集70例PD患者为观察组(PD组),30例健康体检者为对照组,根据Hoehn-Yahr(修正)分级量表(H&Y分期)将PD组分为3个亚组:早期组25例、中期组24例和晚期组21例。应用免疫比浊法检测血清Cys-C水平,比较PD组与对照组血清Cys-C水平的差异及PD组各亚组间血清Cys-C水平的差异;同时分析血清Cys-C与H&Y分期及帕金森病评定量表(UPDRS)运动评分的相关性。结果 PD组患者血清Cys-C水平明显高于对照组,差异具有统计学意义(t=3.61,P<0.01);晚期组血清Cys-C水平明显高于中期组及早期组,差异具有统计学意义(P<0.05,P<0.01);中期组血清Cys-C水平明显高于早期组及对照组,差异具有统计学意义(P<0.01,P<0.01);早期组血清Cys-C水平高于对照组,但差异无统计学意义(t=1.31,P=0.12)。PD组血清Cys-C水平与H&Y分期(r=0.67,P<0.01)、UPDRSⅡ(r=0.64,P<0.01)及UPDRSⅢ(r=0.59,P<0.01)均呈正相关。结论 PD患者血清Cys-C水平升高,且血清Cys-C水平与PD的病程进展相关,可反应病情的严重程度,在PD的进展中起一定作用。Objective To investigate the correlation and clinical significance between serum cystatin C （Cys-C） level and Parkinson＇ s disease（PD）. Methods Seventy patients of PD were selected as the observation group （PD g-roup） ,30 healthy people were selected as the control group, PD group was divided into three subgroups according to the score of H＆Y staging：early stage group（ 25 cases）, medium stage group（ 24 cases）and advanced stage group（21 cases）. A immunology turbidimetric was employed to measure the serum Cys-C levels. Compare the PD group and control group differences in the levels of serum Cys-C, and compare PD group each subgroup differences in the levels of serum Cys-C. At the same time, the correlation between serum Cys-C levels and gender, age, H＆Y staging and U-PDRS motor score were ana- lyzed. Results The serum level of Cys-C was significantly higher in PD group than the control group, the difference is statistically significant （ t = 3.61, P 〈 0.01 ） ; the serum level of Cys-C was significantly higher in the advanced stage group than in the medium stage group and early stage group, the differences are statisticallysignificant （ P 〈 0.05, P 〈 0.01 ） ;the serum level of Cys-C was significantly higher in the medium stage group than in the early stage group and control group, the differences are statistically significant （ P 〈 0.01, P 〈 0.01 ） ; the serum level of Cys-C was higher in the early stage group than in the control group, but the difference was not statistically significant （ t = 1.31, P = 0.12 〉 0.05 ）. Pearson correlation analysis revealed the serum Cys-C level of the PD group had a positive correction with H-Y stage（r = 0.67,P〈0.01） ,UPDRS lI score（r=0.64,P〈0.01）,UPDRS m score（r=0.59,P〈0.01）.Conelusion The serum level of Cys-C was significantly higher in PD than the control group;The serum Cys-C levels associated with the progression of PD, can reflect the severity of the disease and play a role in the development of PD.

关 键 词：半胱氨酸蛋白酶抑制剂C 帕金森病 临床意义 

分 类 号：R742.5[医药卫生—神经病学与精神病学] R446.112[医药卫生—临床医学]